Related Experiment Video
Updated: May 27, 2026
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
A randomized, masked study of weekly erythropoietin dosing in preterm infants
Robin K Ohls1, Mashid Roohi, Hannah M Peceny
1Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA. rohls@salud.unm.edu
Insights
Weekly erythropoietin (EPO) dosing effectively stimulates reticulocyte production in preterm infants, similar to more frequent administration. This suggests a potentially simpler, effective regimen for managing anemia in premature babies.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Hematology
Background:
- Erythropoietin (EPO) is crucial for red blood cell production.
- Optimizing EPO dosing schedules in preterm infants is essential for effective anemia management.
- Current standard practice often involves multiple weekly EPO administrations.
Purpose of the Study:
- To compare the efficacy of once-weekly EPO dosing versus thrice-weekly EPO dosing.
- To evaluate the reticulocyte response in preterm infants receiving different EPO frequencies.
- To assess the impact on hematocrit levels and transfusion requirements.
Main Methods:
- Randomized controlled trial involving preterm infants (≤ 1500 g).
- Two groups received subcutaneous EPO for 4 weeks: once-weekly (1200 U/kg/dose) or thrice-weekly (400 U/kg/dose).
- Both groups received iron and vitamin supplementation; blood counts and reticulocyte counts were monitored.
Main Results:
- Both once-weekly and thrice-weekly EPO increased absolute reticulocyte counts (ARCs) similarly.
- Hematocrit levels remained stable and comparable between groups.
- No significant differences in transfusion needs or adverse events were observed.
Conclusions:
- Once-weekly EPO dosing is effective in stimulating erythropoiesis in preterm infants.
- This dosing schedule maintains stable hematocrit levels and similar transfusion rates compared to thrice-weekly dosing.
- Weekly EPO may offer a more convenient and potentially beneficial therapeutic option for preterm infants requiring enhanced erythropoiesis.
Objective:
To compare reticulocyte responses of once-per-week erythropoietin (EPO) dosing with 3-times-a-week dosing in preterm infants.
Study Design:
Infants weighing ≤ 1500 g and ≥ 7 days of age were randomized to once-per-week EPO, 1200 U/kg/dose, or 3-times-a-week EPO, 400 U/kg/dose, subcutaneously for 4 weeks, along with iron and vitamin supplementation. Complete blood counts, absolute reticulocyte counts (ARCs), transfusions, phlebotomy losses, and adverse events were recorded.
Results:
Twenty preterm infants (962 ± 55 g, 27.9 ± 0.4 weeks, 17 ± 3 days of age) were enrolled. Groups were similar at baseline. Infants in both groups had increased ARCs, which were similar between treatment groups at the start and end of 4 weeks. Hematocrit remained stable, and similar numbers of transfusions were administered. No adverse effects of either dosing schedule were noted.
Conclusions:
Preterm infants respond to weekly EPO by increasing ARCs and maintaining hematocrit. We speculate that once-per-week EPO dosing might be beneficial to preterm infants requiring increased erythropoiesis.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:24Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:14Erythropoiesis
01:14Erythropoiesis